key: cord-1022715-9vzviggq
authors: Noh, Ji Yun; Seo, Yu Bin; Yoon, Jin Gu; Seong, Hye; Hyun, Hakjun; Lee, Jacob; Lee, Nuri; Jung, Seri; Park, Min-Jeong; Song, Wonkeun; Yoon, Jung; Lim, Chae Seung; Ryou, Jungsang; Lee, Joo-Yeon; Kim, Sung-Soon; Cheong, Hee Jin; Kim, Woo Joo; Yoon, Soo-Young; Song, Joon Young
title: Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea
date: 2020-08-20
journal: J Korean Med Sci
DOI: 10.3346/jkms.2020.35.e311
sha: 8a92bd97d3c1505a022d48716145f43a82896200
doc_id: 1022715
cord_uid: 9vzviggq

Serosurveillance studies reveal the actual disease burden and herd immunity level in the population. In Seoul, Korea, a cross-sectional investigation showed 0.07% anti-severe acute respiratory syndrome coronavirus-2 antibody seropositivity among 1,500 outpatients of the university hospitals. Low seroprevalence reflects well-implemented social distancing. Serosurveillance should be repeated as the pandemic progresses.

A total of 1,500 serum samples were collected at two hospitals in southwestern Seoul-Korea University Guro Hospital and Hallym University Kangnam Sacred Heart Hospital. In southwestern Seoul, several clusters of COVID-19 outbreaks occurred at churches, sports clubs, and a call center (Fig. 1) . 5 Moreover, a COVID-19 outbreak occurred at a large distribution center in Bucheon City, Gyeonggi-do Province, which is close to southwestern Seoul. 5 Convenience samples of residual serum samples of outpatients who had visited the hospitals between May 25 and May 29, 2020 were used (Fig. 2) . These patients lived in six administrative districts in southwestern Seoul: Guro-gu, Yeongdeungpo-gu, Gangseo-gu, Yangcheon-gu, Gwanak-gu, and Geumcheon-gu. The serum samples were used anonymously except for the information about sex and age. Serum samples from patients of different ages were collected to investigate the age-stratified seroprevalence of SARS-CoV-2. Samples from patients with laboratory-confirmed COVID-19 were excluded from this study.

The electrochemiluminescence immunoassay (ECLIA) was performed to detect antibodies including immunoglobulin G (IgG) against SARS-CoV-2 using Elecsys ® Anti-SARS-CoV-2 (Roche, Solna, Switzerland) according to the manufacturer's protocol. Elecsys ® Anti-SARS-CoV-2 used a recombinant protein representing the nucleocapsid antigen of SARS-CoV-2 with a double-antigen sandwich assay. 6 Clinical sensitivity of this assay was reported as 99.5% in polymerase chain reaction (PCR)-confirmed SARS-CoV-2 cases when tested at ≥ 14 days post-PCR confirmation and specificity of Elecsys ® Anti-SARS-CoV-2 was reported as 99.8%. 6 A cutoff index (COI, signal sample/cutoff ) of ≥ 1.0 was considered positive for anti-SARS-CoV-2 antibodies. Additionally, a plaque reduction neutralization test (PRNT) was performed for samples that tested positive by ECLIA. Wild-type SARS-CoV-2 (BetaCoV/Korea/ KCDC03/2020) was used for PRNT, and the median neutralizing titer (ND50) was measured.

The study population comprised 48.7% men (730/1,500), and the patient age range was 0-92 years. The patients were divided into the following age groups: 0- 19 California, the United States, the seroprevalence of antibodies to SARS-CoV-2 was 4.06%. 12 In Lombardy, Italy, where the first COVID-19 case was identified on February 20, 2020, the seropositivity rate of neutralizing antibody against SARS-CoV-2 in blood donors was 23.3% (91/390). A seroepidemiological investigation revealed that 1.7% (5/300) of the blood donors collected before identification of the first case tested seropositive against SARS-CoV-2. 13 In a population-based serosurveillance study in Switzerland, 7.9% of the population showed anti-SARS-CoV-2 IgG antibodies. 14 In particular, the seropositivity rate was highest in the 20-49 year age group (9.9%). In the Netherlands, the seroprevalence of antibodies to SARS-CoV-2 was 2.7% among 7,361 blood donors, and seropositivity in donors aged 18-30 years was significantly higher (4.2%) than that in other age groups. 15 The Swedish response to the COVID-19 pandemic aimed to promote herd immunity by allowing a proportion of the population to be infected rather than containing the virus. 16 Nevertheless, the seroprevalence of SARS-CoV-2 antibodies was just 7.3% in Stockholm, Sweden. 17 The seropositive rate of SARS-CoV-2 was higher in young adults than in the elderly in Sweden-4.7%, 6.7%, and 2.7% in the age group of 0-19 years, 20-64 years; and 65-95 years, respectively. 17

In Korea, seroprevalence of antibodies to SARS-CoV-2 among 198 outpatients and their guardians was 7.6% in Daegu in which more than half (56.9%, 6,881/12,088) of domestic cases with COVID-19 occurred as of August 11, 2020. 18 However, because of the heterogeneous and inconsistent results, the clinical performance of SARS-CoV-2 rapid lateral flow assay is still under evaluation, requiring confirmatory testing such as neutralization assay. 19 Considering the possible cross-reactivity from the pre-existing common cold coronaviruses (NL63, 229E, OC43 or HKU1) antibodies, it is necessary to be careful in interpreting the results.

This study has some limitations. First, a selection bias could have existed; hence, the study result might not represent the seroprevalence of antibodies to SARS-CoV-2 in the general population of southwestern Seoul, Korea. Second, epidemiological information of one person who was seropositive was not available. Third, this study was a one-time crosssectional investigation, and seroprevalence may change as the pandemic progresses. Thus, a cross-sectional investigation should be repeated to estimate the herd immunity level. However, this study revealed low seroprevalence of antibodies to SARS-CoV-2 in healthcare facility users in Seoul, Korea. A low seroprevalence (0.07%) reflects that the COVID-19 pandemic is relatively under control by implementation of social distancing and rigorous epidemiological investigations, including contact tracing, active testing, and patient isolation. However, low seroprevalence of SARS-CoV-2 suggests that most people are still vulnerable to SARS-CoV-2 infection. Considering the basic reproduction number of COVID-19, > 60% of the population should be immune against SARS-CoV-2 to suppress the pandemic. Therefore, we are still at the beginning of the pandemic, and we should follow social distancing norms to prevent the explosive spread of COVID-19 until effective vaccines are available. Serosurveillance should be repeated to estimate the level of herd immunity in each country as the pandemic progress.

The study protocol was exempted from review by the Public Institutional Review Board designated by the Ministry of Health and Welfare (approval No. P01-202005-31-006).

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Asymptomatic infection and atypical manifestations of COVID-19: comparison of viral shedding duration

Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers

World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection

Ministry of Health and Welfare (KR)

Statistics of registered foreigners in Seoul (by nationality/ administrative district

Statistics of Seoul resident registered population (by administrative district

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a crosssectional study

Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study

Seroprevalence of SARS-CoV-2-specific antibodies among adults in

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Herd immunity is not a realistic exit strategy during a COVID-19 outbreak

Has Sweden's controversial COVID-19 strategy been successful?

Public Health Agency of Sweden. Första resultaten från pågående undersökning av antikroppar för COVID-19-virus

IgG Seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu

Serodiagnostics for severe acute respiratory syndrome-related coronavirus-2: a narrative review